Trump's trade blitz produces few deals but lots of uncertainty
White House trade adviser Peter Navarro predicted '90 deals in 90 days.'' Administration officials declared that other countries were desperate to make concessions to avoid the massive import taxes – tariffs -- that Trump was threatening to plaster on their products starting July 9.
But the 90 days have come and gone. And the tally of trade deals stands at two – one with the United Kingdom and one with Vietnam. Trump has also announced the framework for a deal with China, the details of which remain fuzzy.
Trump has now extended the deadline for negotiations to Aug. 1 and tinkered with his threatened tariffs, leaving the global trading system pretty much where it stood three months ago — in a state of limbo as businesses delay decisions on investments, contracts and hiring because they don't know what the rules will be.
'It's a rerun, basically,'' said William Reinsch, a former U.S. trade official who's now an adviser with the Center for Strategic and International Studies think tank. Trump and his team 'don't have the deals they want. So they're piling on the threats."
The pattern has repeated itself enough times to earn Trump the label TACO — an acronym coined by The Financial Times' Robert Armstrong that stands for 'Trump Always Chickens Out.'
"This is classic Trump: Threaten, threaten more, but then extend the deadline,' Reinsch said. 'July 30 arrives, does he do it again if he still doesn't have the deals?'' (Trump said Tuesday that there will be no more extensions.)
The deal drought represents a collision with reality.
Negotiating simultaneously with every country on earth was always an impossible task, as Trump himself belatedly admitted last month in an interview with the Fox News Channel. ('There's 200 countries,'' the president said. 'You can't talk to all of them.'') And many trading partners — such as Japan and the European Union — were always likely to balk at Trump's demands, at least without getting something in return.
'It's really, really hard to negotiate trade agreements,' which usually takes several months even when it involves just one country or a small regional group, said Chad Bown, an economic adviser in the Obama White House and now senior fellow at the Peterson Institute for International Economics. 'What the administration is doing is negotiating a bunch of these at the same time.''
The drama began April 2 – "Liberation Day,'' Trump called it — when the tariff-loving president announced a so-called baseline 10% import tax on everybody and what he called 'reciprocal'' levies of up to 50% on countries with which the United States runs trade deficits.
The 10% baseline tariffs appear to be here to stay. Trump needs them to raise money to patch the hole his massive tax-cut bill is blasting into the federal budget deficit.
By themselves, the baseline tariffs represent a massive shift in American trade policy: Tariffs averaged around 2.5% when Trump returned to the White House and were even lower before he started raising them in his first term.
But the reciprocal tariffs are an even bigger deal.
In announcing them, Trump effectively blew up the rules governing world trade. For decades, the United States and most other countries abided by tariff rates set through a series of complex negotiations known as the Uruguay round. Countries could set their own tariffs – but under the 'most favored nation'' approach, they couldn't charge one country more than they charged another.
Now Trump is setting the tariff rates himself, creating 'tailor-made trade plans for each and every country on this planet,'' in the words of White House press secretary Karoline Leavitt.
But investors have recoiled at the audacious plan, fearing that it will disrupt trade and damage the world economy. Trump's Liberation Day tariffs, for instance, set off a four-day rout in global financial markets. Trump blinked. Less than 13 hours after the reciprocal tariffs took effect April 9, he abruptly suspended them for 90 days, giving countries time to negotiate with his trade team.
Despite the Trump administration's expressions of confidence, the talks turned into a slog.
'Countries have their own politics, their own domestic politics,' Reinsch said. 'Trump structured this ideally so that all the concessions are made by the other guys and the only U.S. concession is: We don't impose the tariffs.''
But countries like South Korea and Japan needed 'to come back with something,'' he said. Their thinking: 'We have to get some concessions out of the United States to make it look like this is a win-win agreement and not a we-fold-and-surrender agreement. '
Japan, for example, wanted relief from another Trump tariff — 50% levies on steel and aluminum.
Countries may also be hesitant to reach a deal with the United States while the Trump administration conducts investigations that might result in new tariffs on a range of products, including pharmaceuticals and semiconductors.
Frustrated by the lack of progress, Trump on Monday sent letters to Japan, South Korea and 12 other countries, saying he'd hit them with tariffs Aug. 1 if they couldn't reach an agreement. The levies were close to what he'd announced on April 2; Japan's, for example, would be 25%, compared to the 24% unveiled April 2.
Trump did sign an agreement last month with the United Kingdom that, among other provisions, reduced U.S. tariffs on British automotive and aerospace products while opening the U.K. market for American beef and ethanol. But the pact kept the baseline tariff on British products mostly in place, underlining Trump's commitment to the 10% tax despite the United States running a trade surplus — not a deficit — with the U.K. for 19 straight years, according to the U.S. Commerce Department.
On July 2. Trump announced a deal with Vietnam. The Vietnamese agreed to let U.S. products into the country duty free while accepting a 20% tax on their exports to the United States, Trump said, though details of the agreement have not been released.
The lopsided deal with Vietnam suggests that Trump can successfully use the tariff threat to bully concessions out of smaller economies.
'They just can't really negotiate in the same way that the (European Union) or Korea or Japan (or) Canada can negotiate with the United States,'' said Dan McCarthy, principal in McCarthy Consulting and a former official with the Office of the U.S. Trade Representative in the Biden administration. 'A lot of (smaller) countries just want to get out of this and are willing to cut their losses.''
But wrangling a deal with bigger trading partners is likely to remain tougher.
'The U.S. is gambling that these countries will ultimately be intimidated and fold,' Reinsch said. 'And the countries are gambling that the longer this stretches out, and the longer it goes without Trump producing any more deals, the more desperate he gets; and he lowers his standards.
"It's kind of a giant game of chicken.''
Paul Wiseman, The Associated Press
Error while retrieving data
Sign in to access your portfolio
Error while retrieving data
Error while retrieving data
Error while retrieving data
Error while retrieving data
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
The Open Group Launches The Open Group Open Digital Transformation™ Forum
Standards body aims to spur faster, more effective transformation initiatives SAN FRANCISCO, July 28, 2025--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. "The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation," commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. "By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices." Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. "Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge," said Steve Nunn, President and CEO of The Open Group. "Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment." To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. View source version on Contacts Media contact Monika BoudovaHotwire for The Open GroupUKOpengroup@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio